ClinicalTrials.gg
CompletedNCT03640793Updated Mar 13, 2024

Prospective Evaluation of a Palato-Pharyngeal Implant System (PPIS) Obstructive Sleep Apnea Syndrome (OSAS)

An interventional study of Implantation in Snoring and Obstructive Sleep Apnea, sponsored by Medartis AG. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Medartis AG · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Prospective Evaluation of a Palato-Pharyngeal Implant System (PPIS) for the Treatment of Snoring and Obstructive Sleep Apnea Syndrome (OSAS): A Pilot Study.

Read the detailed description

The clinical study is designed as single center, prospective, non-randomized and non-blinded clinical study. Since the surgical procedure is independent of the population a single center study is applied. A double-blind study is not possible considering the implantation procedure with the surgeon always knowing if the device is set. Therefore, the study is designed to be non-randomized and non-blinded as a pilot trial.

To reduce bias and other influences of single surgeon skills a principal investigator and one investigator are part of the clinical study. Further, subjects with previous treatments such as Pillar implant or previous airway surgery other than nasal, adenoid, tonsil or UPPP are excluded from the clinical study. A double-blind study is not possible considering the implantation procedure with the surgeon always knowing if the device is set. Therefore, the study is designed to be non-randomized and non-blinded as a pilot trial.

02

Conditions studied

  • Snoring
  • Obstructive Sleep Apnea

Keywords

  • Snoring, Obstructive Sleep Apnea
03

In context

Snoring

122 studies on the registry are indexed under Snoring; 15 are open to participants now.

This study's enrollment of 25 is below the median of 43 across 95 interventional studies indexed under Snoring.

Browse Snoring studies →

Lead sponsor

Medartis AG is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Socially disturbing snoring and obstructive sleep apnea syndrome with AHI≥10/h

      • Predominantly retropalatal obstructions established either by:
      • Drug-induced sedation nasendoscopy
      • or ApneaGraph ≥60% (optional)
      • or successful application of the Velumount palatal device (optional)
      • Findings for predominantly retropalatal obstructions in ENT-examination:
      • No tonsils or tonsils grade I
      • Normal finding of larynx and tongue base, no omega-shaped epiglottis
      • No lingual tonsil hypertrophy
      • ASA (American Society of Anaesthesiology, 1963) classes I or II
      • (BMI) \< 30 kg/m2
      • Age > 18 yrs
      • Fix bed partner
      • Ability to read and understand the patient's information

Exclusion criteria

Exclusion Criteria:

    • Previous Pillar implants

      • Medartis palatinal implant (from previous phase I study)
      • Previous airway surgery other than nasal, adenoid, tonsil or UPPP
      • Presence of other sleep disorders
      • Psychiatric disorders
      • Neurological disorders (e.g. Cerebrovascular injury)
      • Dysmorphia of the cranial skeleton
      • Pregnancy or breastfeeding
      • Known to nitinol
      • Participation in another clinical study
      • Recurrent tonsillitis with prescription of antibiotics during the last 2 years (≥3x/year)
      • Omega-shaped epiglottis
      • Lingual tonsil hypertrophy
      • Kinking of the internal carotid artery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Single center, prospective, non-randomized, non-blinded study

    Implantation of 6 PPIS implants in each patient

    Device: Implantation

Interventions

  • DeviceImplantation

    Implantation of 6 PPIS implants

06

What researchers measure

Primary outcomes

  1. AHI reduction

    AHI reduction

    Time frame: 3 months post-op

07

Study locations

1 site
  • Kantonsspital Liestal
    Basel, Basel Land 4410, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Feb 2024, 76 months.

Of 45 interventional studies with no phase under Snoring, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 31. This study's 76 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Aug 21, 2018
StartActual
Oct 9, 2017
Primary completionActual
Feb 13, 2024
CompletionActual
Mar 4, 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03640793
Lead sponsor
Medartis AG
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Oct 9, 2017
Primary completion
Feb 13, 2024
Completion
Mar 4, 2024
Last update
Mar 13, 2024

Study contacts

Kurt Tschopp, MD
principal investigator · Kantonsspital Liestal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion